Thymidylate synthase
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Thymidylate synthase as ChEMBL target CHEMBL2555, mapped to UniProt P0A884. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Thymidylate synthase matters
Thymidylate synthase is reviewed as Thymidylate synthase (UniProt P0A884); Thymidylate synthase shows approved-linked disease relevance led by adenocarcinoma. 4 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 3 approved drugs, 74 compounds, and 20 assays, with lead potency reaching pChEMBL 7.2.
Thymidylate synthase Sequence length is 264 aa.
Review this target as Thymidylate synthase, mapped to UniProt P0A884. Sequence length is 264 aa.
Protein source · UniProt accession via ChEMBL component mappingThymidylate synthase shows approved-linked disease relevance led by adenocarcinoma. 4 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include PEMETREXED TROMETHAMINE.
Start review with adenocarcinoma because it currently carries approved-linked support. Linked drugs include PEMETREXED TROMETHAMINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 3 approved drugs, 74 compounds, and 20 assays for this target. The dominant activity type is KI. CHEMBL422395 is the current potency anchor at pChEMBL 7.2.
Use CHEMBL422395 as the tractability anchor when discussing potency (pChEMBL 7.2).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Thymidylate synthase matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P0A884, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need to see why adenocarcinoma is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL422395
|
7.2 | IC50 | — |
|
|
No preferred name
CHEMBL422395
|
7.0 | Ki | — |
|
|
No preferred name
CHEMBL308223
|
6.6 | Ki | — |
|
|
No preferred name
CHEMBL2323403
|
6.5 | Ki | — |
|
|
No preferred name
CHEMBL67116
|
6.2 | Ki | — |